Does PALBOCICLIB Cause Upper respiratory tract infection? 229 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 229 reports of Upper respiratory tract infection have been filed in association with PALBOCICLIB (Ibrance). This represents 0.3% of all adverse event reports for PALBOCICLIB.
229
Reports of Upper respiratory tract infection with PALBOCICLIB
0.3%
of all PALBOCICLIB reports
6
Deaths
46
Hospitalizations
How Dangerous Is Upper respiratory tract infection From PALBOCICLIB?
Of the 229 reports, 6 (2.6%) resulted in death, 46 (20.1%) required hospitalization, and 1 (0.4%) were considered life-threatening.
Is Upper respiratory tract infection Listed in the Official Label?
Yes, Upper respiratory tract infection is listed as a known adverse reaction in the official FDA drug label for PALBOCICLIB.
What Other Side Effects Does PALBOCICLIB Cause?
Fatigue (15,190)
White blood cell count decreased (11,273)
Neoplasm progression (10,885)
Death (8,410)
Nausea (8,189)
Neutropenia (6,423)
Alopecia (6,201)
Diarrhoea (5,635)
Asthenia (3,660)
Off label use (3,405)
What Other Drugs Cause Upper respiratory tract infection?
ADALIMUMAB (3,306)
ETANERCEPT (2,948)
TOFACITINIB (1,805)
RITUXIMAB (1,713)
ABATACEPT (1,623)
METHOTREXATE (1,576)
TOCILIZUMAB (1,455)
APREMILAST (1,437)
PREDNISONE (1,354)
SECUKINUMAB (1,339)
Which PALBOCICLIB Alternatives Have Lower Upper respiratory tract infection Risk?
PALBOCICLIB vs PALIPERIDONE
PALBOCICLIB vs PALIVIZUMAB
PALBOCICLIB vs PALONOSETRON
PALBOCICLIB vs PAMIDRONATE
PALBOCICLIB vs PAMIDRONIC ACID